Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06345729
Title	A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) >=50% (MK-1084-004)
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme LLC
Indications	lung non-small cell carcinoma
Therapies	Pembrolizumab MK-1084 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| ROU \| NZL \| NLD \| ITA \| GRC \| FRA \| ESP \| CAN \| BRA \| BGR \| AUT \| AUS \| ARG